SciELO - Scientific Electronic Library Online

 
vol.40 issue2Prevalence of opportunistic infections in HIV-AIDS patients based on microscopic examination of bone marrowPrediction model of short-term risk in patients with acute coronary syndrome without ST segment elevation author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Acta Medica Colombiana

Print version ISSN 0120-2448

Abstract

VILLEGAS, Carlos Raúl; CHACON, José Arnoby  and  SANCHEZ, Tomás. Survival in prostate cancer in a population of the center of Colombia. Acta Med Colomb [online]. 2015, vol.40, n.2, pp.101-108. ISSN 0120-2448.

Background: prostate cancer (PC) occupies the first place of occurrence in the US; in developing countries it is between the fourth and sixth place, except in Brazil where it is the first cancer in men. In the West Oncologists S.A. of Colombia records, it ranks sixth in the general population and is the second malignancy in males. Materials and methods: a follow-up of patients treated in the West Oncologists -headquarters of Caldas- was carried out, with an influence population of 1.1 million inhabitants and a total of 12 000 records analyzed from January 1997 to June 2012, for a final report of 404 patients with prostate cancer. Results: the mean age was 69 years, 73% between 61 and 80 years; 56% in clinical stage II (II-A: 22% and II-B: 34%) and 18% stage IV. Gleason Scale less than 6 in 37%, 33% equal to 7 (4 + 3: 49% and 3 + 4: 51%). 30% with PSA between 4 and 10 ng / mL and 13% greater than 100 ng / mL PSA. 36% with some type of prior treatment (prostatectomy and orchiectomy 17%: 9%); 90% with Karnofsky > 80%; 29% relapsed and 73% of those with biochemical relapse; radiotherapy was performed in 92% (60% directed to the primary tumor and 16% to metastasis); stage T1c was found in 41%. The 10-year survival was 94% between 61 and 70 years (p = 0.001). In patients with Gleason </ = 7, 83% survived with no difference between the scores 4 + 3 or 3 + 4 (p = 0.9698). PSA <4 ng / ml 98% and > 20 to 99 ng / mL was 78% (p = 0.001). In patients with relapse, ten-year survival was 68% versus 87% in its absence (p <0.01). Mean follow-up was 40.1 months (interquartile range: 16-52). Survival at five and ten years in localized stage was 92% and 79%; in metastatic disease was 52% and 30% respectively and with regional disease survival was 100% in both five and ten years. Conclusion: this paper analyzes prognostic factors recognized in the world literature applied to patients with prostate cancer in our country, regarding the survival of five to ten years, as a point of reference that can help specialists in the therapeutic decisions and could become a motivation for other Colombian institutions to generate similar research projects. (Acta Med Colomb 2015; 40: 101-108).

Keywords : cancer; prostate; prognostic factors; survival.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )